Toward protecting the safety of participants in clinical trials

被引:40
作者
Califf, RM
Morse, MA
Wittes, J
Goodman, SN
Nelson, DK
DeMets, DL
Iafrate, RP
Sugarman, J
机构
[1] Duke Univ, Clin Res Inst, Med Ctr, Durham, NC 27715 USA
[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[3] Stat Collaborat Inc, Washington, DC USA
[4] Johns Hopkins Sch Med, Baltimore, MD USA
[5] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA
[6] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA
[7] Univ Wisconsin, Dept Stat & Biostat, Madison, WI USA
[8] Univ Florida, Hlth Ctr Inst Review Board, Gainesville, FL USA
[9] Duke Univ, Ctr Med, Ctr Study Med Eth & Humanit, Durham, NC USA
来源
CONTROLLED CLINICAL TRIALS | 2003年 / 24卷 / 03期
基金
美国国家卫生研究院;
关键词
clinical trials; protection; ethics; monitoring; good clinical practices;
D O I
10.1016/S0197-2456(03)00005-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It is a widely held belief that the current system of oversight of clinical research, particularly the means of assessing risks and minimizing harms to participants in clinical trials, could be improved. In particular, the system is inefficient with overemphasis on the monitoring ability of some groups such as research ethics review boards and investigators, underemphasis on others such as data monitoring committees (DMCs) and sponsors, confusion about responsibilities for safety and imperfect communication between these different groups. Research ethics review boards are not able to perform safety monitoring by review of individual adverse events and are often burdened by duplicative reviews of large multicenter studies. There are no standards for DMCs to ensure they can reliably identify safety issues. Sponsors may be overreliant on data audits and slow to disseminate safety data in a coherent summary. Investigators, their staffs and clinical sites may not fully appreciate all the nuances of good clinical practice or may be inattentive to the daily conduct of studies. Regulators, particularly those in the United States, have failed to completely harmonize their policies with each other or with international regulatory agencies. We recommend well-designed monitoring plans for all studies that are appropriate to their scope and risk, more centralized review of large multisite studies and closer local scrutiny of single-institution studies. In addition, sponsors should pay greater attention to monitoring adverse events and keeping up-to-date databases or investigator's brochures emphasizing safety issues. A minimal standard of education or expertise in good clinical practice should be established for investigators, their staffs and research ethics review board members. DMC composition and functions should be standardized and regulations should be harmonized nationally and internationally. Finally, there should be a concerted effort to study the efficacy of various components of the system. (C) 2003 by Elsevier Inc. All rights reserved.
引用
收藏
页码:256 / 271
页数:16
相关论文
共 32 条
  • [1] [Anonymous], 2002, Data monitoring committees in clinical trials: A practical perspective
  • [2] Should all trials have a Data Safety and Monitoring Committee?
    Cairns, JA
    Hallstrom, A
    Held, P
    [J]. AMERICAN HEART JOURNAL, 2001, 141 (01) : 156 - 163
  • [3] Developing systems for cost-effective auditing of clinical trials
    Califf, RM
    Karnash, SL
    Woodlief, LH
    [J]. CONTROLLED CLINICAL TRIALS, 1997, 18 (06): : 651 - 660
  • [4] Sounding board - A central institutional review board for multi-institutional trials.
    Christian, MC
    Goldberg, JL
    Killen, J
    Abrams, JS
    McCabe, MS
    Mauer, JK
    Wittes, RE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) : 1405 - 1408
  • [5] The Data and Safety Monitoring Committee: Some final thoughts
    DeMets, DL
    Yusuf, S
    [J]. AMERICAN HEART JOURNAL, 2001, 141 (04) : 548 - 549
  • [6] Gilger Elizabeth A, 2002, J Pediatr Oncol Nurs, V19, P172
  • [7] *I MED, 2002, PRES PUBL TRUST ACCR
  • [8] Completeness of safety reporting in randomized trials - An evaluation of 7 medical areas
    Ioannidis, JPA
    Lau, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (04): : 437 - 443
  • [9] *J HOPK U EXT REV, 2001, REP RES VOL DEATH
  • [10] *J HOPK U INT INV, 2001, REP INT INV DEATH V